相关实验视频

Updated: Jan 18, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

对于有利和选择不利的中期风险前列腺癌,支臂疗法单疗法

Martin King¹, Grgur Mirić^2,3, Robert Galbreath^2,4

¹Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA. martin_king@dfci.harvard.edu.

Prostate cancer and prostatic diseases

|September 11, 2025

概括

甲状腺疗法单一疗法对有利和不利的中等风险前列腺癌患者有效,cT1-T2a/PSA<10标准. 这种治疗方法可以避免这种患者小组的生化失败.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
泌尿器科泌尿器科泌尿器科泌尿器科

背景情况:

国家综合癌症网络的指导方针支持中等风险前列腺癌的手臂治疗单疗法.
确定特定的患者子组,以进行手臂治疗单一治疗,对于最佳的治疗选择至关重要.

研究的目的:

为了确定适合于中等风险前列腺癌中基疗法单一治疗的特定患者亚组.
根据临床因素和前列腺特异性抗原水平,评估支臂疗法单一疗法的疗效.

主要方法:

对1622名中等风险前列腺癌患者进行了回顾性分析,这些患者接受了与ADT/EBRT或没有ADT/EBRT的胸腔疗法.
生物化学失效 (BF) 定义为PSA>0.4 ng/mL.
细灰和单变量分析以确定BF的风险因素和ADT/EBRT的影响.

主要成果:

在单一治疗中,PSA ≥10 ng/mL和cT2b-c疾病与较高的BF率有关 (17.2%与5.8%相比).
对于cT1-T2a/PSA<10,无论是ADT还是EBRT添加都没有影响BF.
在cT2b-c/PSA ≥10小组中,ADT显著降低了BF,而EBRT没有.

结论:

甲状腺疗法单疗是一种适合和有效的治疗,适用于有利的中间风险 (FIR) 和不利的中间风险 (UIR) 的前列腺癌患者,满足cT1-T2a/PSA<10标准.
抗雄激素剥夺疗法 (ADT) 可能有利于患有较高风险特征的患者 (cT2b-c/PSA ≥10) 当与胸膜疗法结合时.

更多相关视频

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...